FDA NEWS RELEASE
The U.S. Food and Drug Administration today approved Olysio (simeprevir), a new therapy to treat chronic hepatitis C virus infection.
Full Press Release
Fair Pricing Coalition Disappointed by the High Price of New Janssen Hepatitis C Drug Olysio (simeprevir) Read Press Release
Caring Ambassadors Program
Experts Agree: We Can No Longer Ignore
the Burden of Liver Disease
The Liver Cancer Roundtable held their inaugural meeting last week in Washington, DC. The Roundtable attendees included leading academic experts in liver cancer, patient advocates, and representatives from HHS, NIH, and the CDC. Dr. Douglas LaBrecque, who co-chairs the Roundtable and has been spearheading a year-long global effort to raise awareness about liver cancer for the World Gastroenterology Organization, was encouraged by the two-day event. “This was a remarkable gathering of national and international experts,” LaBrecque stated. “The results of their passionate and enthusiastic discussions will provide the basis for a first draft of a National Action Plan for the prevention, diagnosis, care, and treatment of liver cancer.”
The full press release is available here.
Hepatitis C News
Week Ending December 1, 2013
Key part of hepatitis C virus pictured in great detail
‘Scientists have determined the most detailed picture yet of a crucial part of the hepatitis C virus, which the virus uses to infect liver cells. The findings can bring an effective hepatitis C vaccine closer to reality. Researchers at The Scripps Research Institute (TSRI) focused on a protein known as E2 envelope glycoprotein.’
Experts for use of sterilized tools to prevent hepatitis C
‘LAHORE: Health experts on Thursday cautioned that government might not win a battle against the spread of Hepatitis C virus in Pakistan until the use, reuse and misuse of syringes continue across the country. In a public awareness seminar on hepatitis C held here at the University of Health Sciences (UHS) on Thursday, Pakistan’s leading liver and gastroenterology physician and Principal Gujranwala Medical College Gujranwala, Prof Aftab Moshin said out of country’s 200 million, an estimated 16 to 148 million are infected with various forms of hepatitis viruses.’
Low SVR rates observed in HCV/HIV patients assigned peginterferon/ribavirin in clinical practice
‘WASHINGTON — With liver disease now the leading cause of death among patients coinfected with HIV and hepatitis C, treatment of the HCV coinfection should be a key part of the care of HIV-infected patients, a speaker said here.’
New hep C treatments set to overturn US market, says study
‘The upcoming US market launches of two new hepatitis C virus (HCV) treatments will result in current triple– and dual–therapy regimens losing considerable market share, according to new research from BioTrends Research Group.’
J&J HCV drug OK'd; educational push planned
‘Janssen's hepatitis C drug Olysio (simeprevir) scored FDA approval Friday evening, kicking off a new wave of hepatitis C drugs. It offers modest benefit over standard of care, but a subgroup of patients has encountered resistance, and the med could have trouble catching on as newer antivirals become more broadly available for treating the liver–destroying disease.’
For more Hepatitis C In The News, click here
by Benjamin Ryan
The hepatitis C pipeline: huge changes on the horizon
Hepatitis C: Prepare to meet your match. The future is almost here.
CAP-Hepatitis C Get Involved
Act Now to Impact C!
The CAP-Hepatitis C Get Involved provides tools to:
- increase public awareness of hepatitis C
- inform policy makers about current hepatitis C issues
- keep abreast of evolving issues in the hepatitis C community
Together, we can change the course of Hepatitis C.